Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Foyez Mahmud"'
Autor:
Wei Li, Duane D. Miller, Tiffany N. Seagroves, Bernd Meibohm, Pradeep B. Lukka, Dejian Ma, Foyez Mahmud, Rui Wang, Deanna N. Parke, Hao Chen, Kelli L. Hartman, Raisa I. Krutilina, Shanshan Deng
Supplementary Data from Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f3f5a0f2dc3cc685e997464eb825751
https://doi.org/10.1158/1535-7163.22523883.v1
https://doi.org/10.1158/1535-7163.22523883.v1
Autor:
Colleen B. Jonsson, Ryan Whatcott, Bernd Meibohm, Kshatresh Dutta Dubey, Souvik Banerjee, Duane D. Miller, Jyothi Parvathareddy, Walter Reichard, Shalini Yadav, Joshua Thammathong, Surekha Surendranathan, Foyez Mahmud, Sourav Banerjee, Sayo O. Fakayode
Publikováno v:
Journal of Chemical Information and Modeling
COVID-19, an acute viral pneumonia, has emerged as a devastating pandemic. Drug repurposing allows researchers to find different indications of FDA-approved or investigational drugs. In this current study, a sequence of pharmacophore and molecular mo
Autor:
Lingling Ma, Yuxi Wang, Lei Yang, Foyez Mahmud, Duane D. Miller, Stephen W. White, Shanshan Deng, Hao Chen, Keyur Parmar, Wei Li, Sayo O. Fakayode, Bernd Meibohm, Souvik Banerjee, Kinsie E. Arnst, Pradeep B. Lukka, Zhongzhi Wu, Mi-Kyung Yun
Publikováno v:
J Med Chem
Small molecules that interact with the colchicine binding site in tubulin have demonstrated therapeutic efficacy in treating cancers. We report the design, syntheses, and antitumor efficacies of new analogues of pyridopyrimidine and hydroquinoxalinon
Publikováno v:
In Drug Discovery Today: Technologies Summer 2012 9(2):e105-e112
Publikováno v:
Cancer Lett
Lung cancer is the most common cause of cancer associated mortality. Chemotherapeutic agents, such as paclitaxel, are important treatment options but drug resistance often develops upon prolonged use. We report here the preclinical evaluation of a ne
Autor:
Woo-Chan Son, Seung Woo Chung, Hyo Won Chang, Youngro Byun, Gui Chul Kim, Foyez Mahmud, Seho Kweon, Jeong Uk Choi, Ji Won Kim, Hanul Lee, Sang Yoon Kim
Publikováno v:
Biomaterials. 182:35-43
Metronomic chemotherapy, which is defined as a low-dose and frequent administration of cytotoxic drugs without drug-free breaks, has been recently emerged as an alternative to traditional MTD therapy and has shown therapeutic benefit in breast cancer
Autor:
Jeong Uk Choi, Sojung Lee, Dong Soo Lee, Jooho Park, Youngro Byun, Ok-Cheol Jeon, Farzana Alam, Jin Woo Park, Foyez Mahmud, Ruby Maharjan
Publikováno v:
Journal of Controlled Release. 284:160-170
There is a growing interest in preclinical research to consider low-dose metronomic chemotherapy as antiangiogenic cancer treatment. Oral metronomic therapy, in particular, has shown much promise with its ease of daily administration and higher thera
Autor:
Ji Won Kim, Seung Woo Chung, Ok Cheol Jeon, Hanul Lee, Young Seok Cho, Seong Who Kim, Seho Kweon, Beom Suk Lee, In San Kim, Sang Yoon Kim, Youngro Byun, Jeong Uk Choi, Gui Chul Kim, Foyez Mahmud
Publikováno v:
International Journal of Cancer. 141:1912-1920
Chemotherapy have commonly been used in maximum tolerated dose to completely eradicate the cancer. However, such treatments often failed due to the complex and dynamic nature of cancer. Therefore, it has been suggested that cancer should be treated a
Autor:
Taslim A. Al-Hilal, Farzana Alam, Seung Woo Chung, Youngro Byun, Jee-Heon Jeong, Jooho Park, Jeong Uk Choi, Foyez Mahmud, Sang Yoon Kim
Publikováno v:
Biomaterials. 139
Clinical studies have found that the incidence of cancer metastasis through the lymphatic vessels are 3-5 times higher than that through the blood vessels. These findings suggest the potency of anti-lymphangiogenic therapy in reducing the incidence o
Autor:
Youngro Byun, Foyez Mahmud, Sang Yoon Kim, Hansung Kim, Seung Woo Chung, Dong-Hyun Seo, Farzana Alam, Taslim A. Al-Hilal
Publikováno v:
Biomaterials. 35:6543-6552
Angiogenesis, the formation of new blood vessels, plays a pivotal role in tumor progression and for this reason angiogenesis inhibitors are an important class of therapeutics for cancer treatment. Heparin-based angiogenesis inhibitors have been newly